The agenda that will shape pharma's future

October 2nd
Start: 8:45am Finish: 5:30pm

October 3rd
Start 9:00am Finish 4:30pm

Full Agenda

Keynote
09:00 – 09:30
We all work in patient engagement now. Let’s make it work.
  • Convert the laggard critics with a narrative and evidence that justifies your patient-first approach, regardless of function
  • No more check-boxes: build a structure where patient engagement is a non-discretionary, genuine constant through every stage of development

Liz Lewis Head of Global Oncology Patient Value, Policy and Access Takeda

09:00 – 09:30
Panel: Why your company’s patient commitment starts in the boardroom
  • Culture eats strategy: how to support leadership in making the case for patient centricity through proven success and identifiable change
  • How to find and support champions across your company

Jan Nissen Vice President, Patient Innovation & Engagement Merck

Edward Trott Chief Patient Officer Ferring

09:00 – 09:30
CSL’s framework that embeds patient focus at every level of the company
  • Learn how CSL’s patient centric mindset is being translated into actionable strategies across the product lifecycle
  • Understand the importance of executive buy in to the vision and its execution
  • Discuss the challenges and learnings of implementation, including the importance of shifting culture to meet strategy

Metani Rooms CMO Strategic Initiatives, Global Lead CSL Behring

09:00 – 09:30
Case Study: From a blank canvas, see how Genentech were able to build a new patient engagement function from the ground up
  • Second-mover advantage: see how Genentech built the frameworks, using best practice, that enabled a fresh approach to engagement
  • Understand why Genentech now believes 80% of each project design should come from the patient voice – and how to figure out the other 20%!

Laurie Meyers Head of Patient Engagement Genentech

09:00 – 09:30
An essential briefing on the FDA's work to advance the patient voice as a contributor to key decisions
  • The latest: get an update directly from FDA staff responsible for engagement
  • How patient advocates can actively engage with the FDA
  • Why Patient-Reported Outcomes are becoming more integral to FDA decision making

FDA speaker announced soon

09:00 – 09:30
Patient-led Roundtable Discussions
09:00 – 09:30
Why We Resist: The Surprising Truths about Motivating Behavior Change
  • We all set healthcare intentions for ourselves. We want to do better. We want to feel better. What holds us back from succeeding?
  • Hear from a behavioral scientist and healthcare marketer about the nine principles of influence that reveal why people reject healthcare change
  • Discover new ways to design communications, interventions and programs to help people make better, more confident decisions about their health

Kathleen Starr Managing Director of Behavioral Science Syneos Health

Leigh Householder Managing Director of Innovation Syneos Health

Join the industry’s innovators, register now to save $100
Digital Patient Solutions
09:00 – 09:30
Case Study: How Takeda and MIT innovated the engagement paradigm to ensure greater insights and understanding in paediatric care
  • Witness Takeda and MIT Media Lab’s reimagination of PRO collection with children in pediatric care
  • Gamification isn’t dead: tailor your engagement methods to quicken patient progression in appropriate audience segments
  • Sharing is caring: why Takeda are making their core IP open-source, once it has received FDA Approval

Magdalena Schoeneich Global Head of Takeda Digital Accelerator, R&D Takeda

09:00 – 09:30
Panel: Is Digital the approach or the answer?
  • Start with the patient: how a patient-first approach has ensured Otsuka’s solutions are driven with purpose, not technology
  • Mix the key ingredients to a successful digital platform that your patients can use and understand
  • Best-practice guidelines on avoiding low take-up of digital solutions by patients

Surbhi Pandit-Patel Associate Director, Digital Solutions Patient Support Otsuka

Sarah Mills Principal, Digital Customer Experience Genentech

09:00 – 09:30
Case Study: Why Ipsen turned to digital methods in initiatives to improve adherence
  • See why the key to Ipsen’s success was to fit their product around the daily lives of their patients
  • Learn from other industries on how they engage with their customers at every point of the product journey to improve adherence

Meghan Hover Szczech Director, Patient Services Ipsen

09:00 – 09:30
Spotlyte: Allergan’s innovative approach that speaks to patients as consumers
  • Learn from Allergan’s game changing approach that treats patients as healthcare consumers
  • See how Spotlyte solved the problems of credibility, personalization and informed decision making that healthcare consumers face everyday
  • Understand how you can use the Spotlyte framework and principles to change the way you communicate with your patient population

Erin Russell General Manager, Spotlyte Allergan

Optimize Patient Partnerships
09:00 – 09:30
Case Study: How the mutual benefits of active listening created a new dynamic for AstraZeneca and it’s patients
  • How listening and understanding to the patient enhanced AstraZeneca’s ability to help it’s patients
  • Why active listening allows for a mutually beneficial partnership between the patient and the pharma company

Michele Teufel Feasibility & Recruitment Partner / Clinical Operations, Global Product Delivery AstraZeneca

09:00 – 09:30
Panel: Why a holistic patient experience cannot exist without a holistic approach to working within your walls
  • Remove the “that’s not my department” mentality from your company’s engagement to spur more meaningful initiatives
  • If you don’t know how each function works with patients, how can the patient? across different functions for a seamless patient experience

Desiree Priestley Director, Patient Support Strategy & Insights Otsuka

Wendy Erler Vice President, Head of Patient Insights and Advocacy Alexion

Andrew Schorr Co-founder Patient Power

09:00 – 09:30
Design an Effective and Compliant Nurse Educator Program to Support Unmet Needs
  • Discover key strategies that impact effective and compliant program design
  • Define the role of the nurse educator and how to appropriately engage with field teams
  • Identify compliant ways to measure Nurse Educator effectiveness

Andrea Heslin Smiley President and CEO VMS Biomarketing

09:00 – 09:30
Panel: Should the ‘Why’ be the ROI? Focus on patient value, knowing that will bring your company ROI in the long-term
  • Understand why seeking direct ROI for patient engagement can hinder your performance in gaining insights
  • Examine whether your company should transition to a model that doesn’t focus on ROI as proof of success in patient relations
  • How to wisen patients to their own healthcare options to show clinical trials as a viable treatment option

Nan Doyle Patient Engagement Lead, Rare Diseases Takeda

Ann Hartry Vice President, HEOR Lundbeck

Lode Dewulf Chief Patient Officer Servier

09:00 – 09:30
Compliance as your cheerleader: How to innovate without being killed by legal
  • Build a compliant governance structure that can keep pace with project needs across function teams, even as they innovate
  • Case Study: How Sanofi have built a framework that allows for oversight without stifling innovation
  • Create an organization-wide pipeline to coordinate patient data more effectively

Speaker released soon

09:00 – 09:30
Case Study: How one pharma company has connected hundreds of patient groups around the world
  • Dive into a global advocacy initiative to connect similar advocacy groups with each other, enable learning, foster collaboration and driving economies of scale
  • Assist advocacy groups to build their own network so they can become the best partners in healthcare possible

Speaker released soon

09:00 – 09:30
Case study: Learn about the Patient-Focused Drug Development Council model as a way to leverage patient insights throughout the drug development process
  • Forming a standing council that enables on-going dialogue and sharing of insights delivers benefits far beyond the typical advisory board
  • Learn about how a PFDD Council was planned and implemented to support clinical trial design and PRO development for a multiple sclerosis program
  • EMD Serono, Accelerated Cure Project, and patient representatives will share their perspectives and key accomplishments of the Council

Schiffon Wong Executive Director, Global Evidence & Value Developmen EMD Serono

Robert McBurney Chief Executive Officer Accelerated Cure Project

Join the industry’s innovators, register now to save $100
Patient-Centered Trial Design as a Minimum Standard
09:00 – 09:30
Panel: Better trial design through pro-active patient collaboration
  • How to ensure enrolment and retention rates are boosted by specific efforts when involving patients in the design and development of trials
  • Build a trial that will keep patients engaged, committed and motivated to the trial through patient-designed PROs
  • Case study: See how Janssen’s proactive engagement helped avoid many problems that occur as trial development advanced

Maura Snyder Director, Patient Engagement Strategy Janssen

Melissa Dupont Patient Network Manager Sanofi

09:00 – 09:30
Case Study: Examine how Janssen’s Global Trial Community is able to provide a holistic experience for patients
  • See Janssen’s new Alumni program that keeps patients engaged in their trial community through interactive patient data return
  • Learn from your patient too: why this new apparatus has improved Janssen’s knowledge about their protocol design

John Ziobrowski Director, Clinical Insights and Experience Janssen

09:00 – 09:30
How patient groups are developing their own registries, and we can all benefit
  • Learn why patient groups are developing their own data sources and how your company can work with them
  • Ways to reduce the burden on RCTs through access to patient registry data

Speaker released soon

Make Patient-Focused Drug Development a Reality
09:00 – 09:30
Rethink early stage research with stronger patient insights
  • A guide to partnering with patients with the intention of discover new research opportunities
  • How to structure patient engagement to ensure you fully understand unmet need
  • Understand how best to translate insights into clinical strategy

Speaker released soon

09:00 – 09:30
Case Study: How Janssen is ensuring its trials are representative of its patient populations
  • Why Janssen has prioritized efforts which is improve diversity of the company’s clinical trials
  • Treat the cause, not the symptoms: understand the true reasons why your patient populations are underrepresented as a key step in improving your trial diversity

Cassandra Smith Diversity and Inclusion in Clinical Trials Lead Janssen

09:00 – 09:30
Case Study: Engage with social media to upscale your Clinical Trial Recruitment
  • Engage your patient population in the place they receive their information, to increase trial enrolment
  • Remove the stigma and clinical trials by presenting your information in a digestible and accessible format

Speaker released soon

09:00 – 09:30
Case Study: Pfizer’s new commitment to being bilingual in patient-speak and industry-speak in everything it says
  • Dive into Pfizer’s new processes for translating the data it disseminates into patient-friendly language to avoid being lost in translation
  • Build trust in your organization by extending transparency: inform patients of what you’re doing at every turn

J. R. Meloro Global Head of Disclosure, Publications, and Transparency Pfizer

09:00 – 09:30
Health Literacy: A Prescription to end Confusion
  • Case Study: How Merck have improved Health Literacy rates and other benefits by addressing the issue pro-actively
  • Medicine is not enough: why health literacy is a vital way to improving outcomes for treatments already on the market

Lori Hall Director - Global Health Literacy Eli Lilly

Laurie Myers Global Health Literacy Director Merck

Keynotes

Keynote
09:00 – 09:30
We all work in patient engagement now. Let’s make it work.
  • Convert the laggard critics with a narrative and evidence that justifies your patient-first approach, regardless of function
  • No more check-boxes: build a structure where patient engagement is a non-discretionary, genuine constant through every stage of development

Liz Lewis Head of Global Oncology Patient Value, Policy and Access Takeda

09:00 – 09:30
Panel: Why your company’s patient commitment starts in the boardroom
  • Culture eats strategy: how to support leadership in making the case for patient centricity through proven success and identifiable change
  • How to find and support champions across your company

Jan Nissen Vice President, Patient Innovation & Engagement Merck

Edward Trott Chief Patient Officer Ferring

09:00 – 09:30
CSL’s framework that embeds patient focus at every level of the company
  • Learn how CSL’s patient centric mindset is being translated into actionable strategies across the product lifecycle
  • Understand the importance of executive buy in to the vision and its execution
  • Discuss the challenges and learnings of implementation, including the importance of shifting culture to meet strategy

Metani Rooms CMO Strategic Initiatives, Global Lead CSL Behring

09:00 – 09:30
Case Study: From a blank canvas, see how Genentech were able to build a new patient engagement function from the ground up
  • Second-mover advantage: see how Genentech built the frameworks, using best practice, that enabled a fresh approach to engagement
  • Understand why Genentech now believes 80% of each project design should come from the patient voice – and how to figure out the other 20%!

Laurie Meyers Head of Patient Engagement Genentech

09:00 – 09:30
An essential briefing on the FDA's work to advance the patient voice as a contributor to key decisions
  • The latest: get an update directly from FDA staff responsible for engagement
  • How patient advocates can actively engage with the FDA
  • Why Patient-Reported Outcomes are becoming more integral to FDA decision making

FDA speaker announced soon

09:00 – 09:30
Patient-led Roundtable Discussions
09:00 – 09:30
Why We Resist: The Surprising Truths about Motivating Behavior Change
  • We all set healthcare intentions for ourselves. We want to do better. We want to feel better. What holds us back from succeeding?
  • Hear from a behavioral scientist and healthcare marketer about the nine principles of influence that reveal why people reject healthcare change
  • Discover new ways to design communications, interventions and programs to help people make better, more confident decisions about their health

Kathleen Starr Managing Director of Behavioral Science Syneos Health

Leigh Householder Managing Director of Innovation Syneos Health

Commercial

Digital Patient Solutions
09:00 – 09:30
Case Study: How Takeda and MIT innovated the engagement paradigm to ensure greater insights and understanding in paediatric care
  • Witness Takeda and MIT Media Lab’s reimagination of PRO collection with children in pediatric care
  • Gamification isn’t dead: tailor your engagement methods to quicken patient progression in appropriate audience segments
  • Sharing is caring: why Takeda are making their core IP open-source, once it has received FDA Approval

Magdalena Schoeneich Global Head of Takeda Digital Accelerator, R&D Takeda

09:00 – 09:30
Panel: Is Digital the approach or the answer?
  • Start with the patient: how a patient-first approach has ensured Otsuka’s solutions are driven with purpose, not technology
  • Mix the key ingredients to a successful digital platform that your patients can use and understand
  • Best-practice guidelines on avoiding low take-up of digital solutions by patients

Surbhi Pandit-Patel Associate Director, Digital Solutions Patient Support Otsuka

Sarah Mills Principal, Digital Customer Experience Genentech

09:00 – 09:30
Case Study: Why Ipsen turned to digital methods in initiatives to improve adherence
  • See why the key to Ipsen’s success was to fit their product around the daily lives of their patients
  • Learn from other industries on how they engage with their customers at every point of the product journey to improve adherence

Meghan Hover Szczech Director, Patient Services Ipsen

09:00 – 09:30
Spotlyte: Allergan’s innovative approach that speaks to patients as consumers
  • Learn from Allergan’s game changing approach that treats patients as healthcare consumers
  • See how Spotlyte solved the problems of credibility, personalization and informed decision making that healthcare consumers face everyday
  • Understand how you can use the Spotlyte framework and principles to change the way you communicate with your patient population

Erin Russell General Manager, Spotlyte Allergan

Optimize Patient Partnerships
09:00 – 09:30
Case Study: How the mutual benefits of active listening created a new dynamic for AstraZeneca and it’s patients
  • How listening and understanding to the patient enhanced AstraZeneca’s ability to help it’s patients
  • Why active listening allows for a mutually beneficial partnership between the patient and the pharma company

Michele Teufel Feasibility & Recruitment Partner / Clinical Operations, Global Product Delivery AstraZeneca

09:00 – 09:30
Panel: Why a holistic patient experience cannot exist without a holistic approach to working within your walls
  • Remove the “that’s not my department” mentality from your company’s engagement to spur more meaningful initiatives
  • If you don’t know how each function works with patients, how can the patient? across different functions for a seamless patient experience

Desiree Priestley Director, Patient Support Strategy & Insights Otsuka

Wendy Erler Vice President, Head of Patient Insights and Advocacy Alexion

Andrew Schorr Co-founder Patient Power

09:00 – 09:30
Design an Effective and Compliant Nurse Educator Program to Support Unmet Needs
  • Discover key strategies that impact effective and compliant program design
  • Define the role of the nurse educator and how to appropriately engage with field teams
  • Identify compliant ways to measure Nurse Educator effectiveness

Andrea Heslin Smiley President and CEO VMS Biomarketing

09:00 – 09:30
Panel: Should the ‘Why’ be the ROI? Focus on patient value, knowing that will bring your company ROI in the long-term
  • Understand why seeking direct ROI for patient engagement can hinder your performance in gaining insights
  • Examine whether your company should transition to a model that doesn’t focus on ROI as proof of success in patient relations
  • How to wisen patients to their own healthcare options to show clinical trials as a viable treatment option

Nan Doyle Patient Engagement Lead, Rare Diseases Takeda

Ann Hartry Vice President, HEOR Lundbeck

Lode Dewulf Chief Patient Officer Servier

09:00 – 09:30
Compliance as your cheerleader: How to innovate without being killed by legal
  • Build a compliant governance structure that can keep pace with project needs across function teams, even as they innovate
  • Case Study: How Sanofi have built a framework that allows for oversight without stifling innovation
  • Create an organization-wide pipeline to coordinate patient data more effectively

Speaker released soon

09:00 – 09:30
Case Study: How one pharma company has connected hundreds of patient groups around the world
  • Dive into a global advocacy initiative to connect similar advocacy groups with each other, enable learning, foster collaboration and driving economies of scale
  • Assist advocacy groups to build their own network so they can become the best partners in healthcare possible

Speaker released soon

09:00 – 09:30
Case study: Learn about the Patient-Focused Drug Development Council model as a way to leverage patient insights throughout the drug development process
  • Forming a standing council that enables on-going dialogue and sharing of insights delivers benefits far beyond the typical advisory board
  • Learn about how a PFDD Council was planned and implemented to support clinical trial design and PRO development for a multiple sclerosis program
  • EMD Serono, Accelerated Cure Project, and patient representatives will share their perspectives and key accomplishments of the Council

Schiffon Wong Executive Director, Global Evidence & Value Developmen EMD Serono

Robert McBurney Chief Executive Officer Accelerated Cure Project

Clinical

Patient-Centered Trial Design as a Minimum Standard
09:00 – 09:30
Panel: Better trial design through pro-active patient collaboration
  • How to ensure enrolment and retention rates are boosted by specific efforts when involving patients in the design and development of trials
  • Build a trial that will keep patients engaged, committed and motivated to the trial through patient-designed PROs
  • Case study: See how Janssen’s proactive engagement helped avoid many problems that occur as trial development advanced

Maura Snyder Director, Patient Engagement Strategy Janssen

Melissa Dupont Patient Network Manager Sanofi

09:00 – 09:30
Case Study: Examine how Janssen’s Global Trial Community is able to provide a holistic experience for patients
  • See Janssen’s new Alumni program that keeps patients engaged in their trial community through interactive patient data return
  • Learn from your patient too: why this new apparatus has improved Janssen’s knowledge about their protocol design

John Ziobrowski Director, Clinical Insights and Experience Janssen

09:00 – 09:30
How patient groups are developing their own registries, and we can all benefit
  • Learn why patient groups are developing their own data sources and how your company can work with them
  • Ways to reduce the burden on RCTs through access to patient registry data

Speaker released soon

Make Patient-Focused Drug Development a Reality
09:00 – 09:30
Rethink early stage research with stronger patient insights
  • A guide to partnering with patients with the intention of discover new research opportunities
  • How to structure patient engagement to ensure you fully understand unmet need
  • Understand how best to translate insights into clinical strategy

Speaker released soon

09:00 – 09:30
Case Study: How Janssen is ensuring its trials are representative of its patient populations
  • Why Janssen has prioritized efforts which is improve diversity of the company’s clinical trials
  • Treat the cause, not the symptoms: understand the true reasons why your patient populations are underrepresented as a key step in improving your trial diversity

Cassandra Smith Diversity and Inclusion in Clinical Trials Lead Janssen

09:00 – 09:30
Case Study: Engage with social media to upscale your Clinical Trial Recruitment
  • Engage your patient population in the place they receive their information, to increase trial enrolment
  • Remove the stigma and clinical trials by presenting your information in a digestible and accessible format

Speaker released soon

09:00 – 09:30
Case Study: Pfizer’s new commitment to being bilingual in patient-speak and industry-speak in everything it says
  • Dive into Pfizer’s new processes for translating the data it disseminates into patient-friendly language to avoid being lost in translation
  • Build trust in your organization by extending transparency: inform patients of what you’re doing at every turn

J. R. Meloro Global Head of Disclosure, Publications, and Transparency Pfizer

09:00 – 09:30
Health Literacy: A Prescription to end Confusion
  • Case Study: How Merck have improved Health Literacy rates and other benefits by addressing the issue pro-actively
  • Medicine is not enough: why health literacy is a vital way to improving outcomes for treatments already on the market

Lori Hall Director - Global Health Literacy Eli Lilly

Laurie Myers Global Health Literacy Director Merck

Don’t pay lip-service to patient centricity.
Make it happen.